(688013)"Touchstone International Medical Science Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688013 · · 13 pages · Chinese
Summary by 6ix AI
The report indicates a significant decline in revenue and net profit compared to the same period last year, attributed mainly to reduced sales of core products. The company also reported a decrease in cash flow from operating activities, reflecting the impact of lower income and increased research and development expenditures. Overall, the report emphasizes the board's commitment to ensuring the accuracy and completeness of the financial information presented.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Touchstone International Medical Science Co. Ltd. on 6ix
Earlier from Touchstone International Medical Science
- (688013)"Touchstone International Medical Science Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
- Announcement on Convening the 2026 Semi-annual Collective Performance Briefing for the STAR Market Medical Device and Medical Equipment Industry
- Announcement on the Expiration of the Shareholding Reduction Plan of Directors and Senior Management and the Results of Shareholding Reduction
- Announcement on Progress in Repurchasing Shares through Call Auction
- Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
Follow Touchstone International Medical Science into a list and get an email when it puts out news.
Follow Touchstone International Medical Science